To include your compound in the COVID-19 Resource Center, submit it here.

Dapagliflozin: Phase III data

A double-blind Phase III trial in 638 treatment-naïve patients with Type II diabetes showed that 10 mg dapagliflozin plus extended-release metformin XR met the primary endpoint of significantly reducing HbA1c from baseline to week

Read the full 341 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE